Preventing and treating Alzheimer's disease: Strategies and prospects

Expert Review of Neurotherapeutics

Volumn 3, Issue 5, 2003, Pages 565-569

  Drachman, David A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; DONEPEZIL; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; RIVASTIGMINE; TACRINE;

AGING; ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DNA MODIFICATION; DRUG MECHANISM; EDITORIAL; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; PATHOGENESIS; PROPHYLAXIS; TREATMENT PLANNING;

EID: 0042377128     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.5.565     Document Type: Editorial

References (39)

1. Katzman R. The prevalence and malignancy of Alzheimer's disease. Arch. Neurol. 33, 217 (1976).
2. Katzman R, Bick K. Alzheimer's Disease: the Changing View. New York Academic Press, NY, USA (2000).
3. Pollen DA. Hannah's Heirs: the Quest For the Genetic Origins of Alzheimer's Disease. Oxford University Press, NY, USA (1993).
4. Bernheimer H, Hornykiewicz, O. Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism. Klin. Wochenschr. 43, 711-715 (1965).
5. Drachman D, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol. 30, 113-121 (1974).
6. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99(3), 459-496 (1976).
7. White P, Hiley CR, Goodhardt MJ et al. Neocortical cholinergic neurons in elderly people. Lancet 1(8013), 668-671 (1977).
8. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2(8000), 1403 (1976).
9. Davies P, Verth AH. Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains. Brain Res. 138(2), 385-392 (1977).
10. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10(2), 122-126 (1981).
11. Summers WK, Viesselman JO, Marsh GM, Candelora K. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol. Psych. 16(2), 145-153 (1981).
12. Davis KL, Thal LJ, Gamzu ER et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N. Engl. J. Med. 327(18), 1253-1259 (1992).
13. Francis PT, Palmer AM, Sims NR et al. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. Engl. J. Med. 313(1), 7-11 (1985).
14. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Com. 120(3), 885-890 (1984).
15. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. NY Acad. Sci. 924, 17-25 (2000).
16. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594), 789-791 (2002).
17. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. 43, 545-584 (2003).
18. Schenk D, Seubert P, Ciccarelli RB. Immunotherapy with β-amyloid for Alzheimer's disease: a new frontier. DNA Cell. Biol. 20(11), 679-681 (2001).
19. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J. Neurosci. 23(13), 5531-5535 (2003).
20. Price DL, Whitehouse PJ, Struble RG et al. Alzheimer's disease and Down's syndrome. Ann. NY Acad. Sci. 396, 145-164 (1982).
21. Wisniewski HM, Rabe A. Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome. Ann. NY Acad. Sci. 477, 247-260 (1986).
22. Goate A. Molecular genetics of Alzheimer's disease. Geriatrics 52(Suppl. 2), S9-S12 (1997).
23. St George-Hyslop P, Haines J et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nature Gen. 2(4), 330-334 (1992).
24. Saunders A, Strittmatter W, Schmechel D et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472 (1993).
25. Mayeux R, Saunders A, Shea S et al. Utility of apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N. Engl. J. Med 338, (1998).
26. Duff K, Eckman C, Zehr C et al. Increased amyloid-β 42(43) in brains of mice expressing mutant presenilin I. Nature 383(6602), 710-713 (1996).
27. Savonenko AV, Xu GM, Price DL, Borchelt DR, Markowska AL. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol. Dis. 12(3), 194-211 (2003).
28. Refolo LM, Pappolla MA, LaFrancois J et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8(5), 890-899 (2001).
29. Seshadri S, Drachman D, Lippa C. Apolipoprotein E e4 allele and the lifetime risk of Alzheimer's disease: what physicians know and what they should know. Arch. Neurol. 52, 1074-1080 (1995).
30. Drachman D. Aging and the brain: a new frontier. Ann. Neurol. 42, 819-828 (1997).
31. Beal M. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357-366 (1995).
32. Wei Y-H, Kao S-H, Lee H-C. Simultaneous increase of mitochondrial DNA delections and lipid peroxidation in human aging. In: Pharmacological Intervention in Aging and Age-Associated Disorders. Kitani K, Aoba A, Goto S (Eds). New York Academy of Sciences, NY, USA, 24-43 (1996).
33. Buee L, Hof PR, Bouras C et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathologica 87(5), 469-480 (1994).
34. Sparks DL, Hunsaker JC 3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 11(6), 601-607 (1990).
35. Strittmatter W, Saunders A, Schmechel D et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of Type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl Acad. Sci. USA 90, 1977-1981 (1993).
36. Jick H, Zornberg G, Jick S, Seshadri S, Drachman D. Statins and the risk of dementia. Lancet 356, 1627-1631 (2000).
37. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57(10), 1439-1443 (2000).
38. Rockwood K, Kirkland S, Hogan DB et al. Use of lipid-lowering agents, indication bias and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59(2), 223-227 (2002).
39. Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98(10), 5856-5861 (2001).